Intellipharmaceutics (IPCI) 1.73 $IPCI Intellip
Post# of 273330
Posted On: 09/02/2016 3:21:39 AM
Intellipharmaceutics (IPCI) 1.73 $IPCI
Intellipharmaceutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Thu Aug 25, 3:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"
, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the 18 Annual Rodman & Renshaw Global Investment Conference on September 13, 2016. Domenic Della Penna, Chief Financial Officer, will be presenting at 2:10 P.M. (Eastern Time) in the Lotte New York Palace Hotel in New York City.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics Closes Public Offering for US$5.2 Million
GlobeNewswire - Mon Jun 06, 4:30PM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today the closing of its previously announced underwritten public offering of 3,229,814 units of common shares and warrants, at a price of US$1.61 per unit, for gross proceeds of approximately US$5.2 million. The Company sold units comprised of an aggregate of 3,229,814 common shares and warrants to purchase an additional 1,614,907 common shares. The underwriter also purchased additional warrants to acquire 240,390 common shares pursuant to the over-allotment option exercised in part by the underwriter. The warrants are exercisable immediately, have a term of five years and an exercise price of US$1.93 per common share. After underwriting discounts and commissions and estimated offering expenses, the Company received net proceeds of approximately US$4.6 Million.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
IIROC Trade Resumption - I
CNW Group - Fri May 27, 8:45AM CDT
Trading resumes in:
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
IIROC Trade Resumption - Intellipharmaceutics International Inc.
Newsfile Corp - Fri May 27, 8:42AM CDT
Trading resumes in:
IPCI: 1.73 (-0.03)
IIROC Trade Halt - Intellipharmaceutics International Inc.
Newsfile Corp - Fri May 27, 8:31AM CDT
The following issues have been halted by IIROC:
IPCI: 1.73 (-0.03)
Intellipharmaceutics Announces Pricing of $5.2 Million Public Offering of Common Shares and Warrants
GlobeNewswire - Fri May 27, 8:30AM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the pricing of an underwritten public offering of 3,229,814 units of common shares and warrants, at a price of US$1.61 per unit, equal to the closing price of the Company's shares on the NASDAQ on May 26, 2016. In connection with the offering, the Company will be issuing an aggregate of 3,229,814 common shares and warrants to purchase an additional 1,614,907 common shares. The warrants will be exercisable immediately, have a term of five years and an exercise price of US$1.93 per common share. After underwriting discounts and commissions and estimated offering expenses, the Company expects to receive net proceeds of approximately US$4.6 million.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
IIROC Trading Halt - I
CNW Group - Fri May 27, 8:30AM CDT
The following issues have been halted by IIROC:
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants
GlobeNewswire - Thu May 26, 4:24PM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it intends to offer units of its common shares and warrants in an underwritten public offering. Dawson James Securities, Inc. is acting as sole bookrunner for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceuticals International's CFO Domenic Della Penna Interviewed by The Life Sciences Report
Marketwired - Thu May 12, 8:02AM CDT
SAN FRANCISCO, CA--(Marketwired - May 12, 2016) - Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: I) has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report, as well as a robust pipeline of generic options for a variety of indications.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics Reports Director Election Results
GlobeNewswire - Tue Apr 19, 4:30PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company", a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reports, as required by TSX rules, that the six nominees, each of whom was an incumbent director of the Company, identified in the Management Information Circular dated March 11, 2016 (the "Circular" were elected as directors of the Company at the annual and special meeting of shareholders of the Company held today (the "Meeting". The voting results, as set out in the scrutineer's report for the Meeting, were as follows:
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics Announces First Quarter 2016 Results
GlobeNewswire - Fri Apr 15, 5:30AM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company", a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 29, 2016. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference
GlobeNewswire - Tue Jan 19, 9:00AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company", a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the Noble Financial Capital Markets' 12 Annual Investor Conference on January 20, 2016. The presentation will take place at 9:00 A.M. (EST) at the Club Med, Sandpiper Bay, Florida.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics Up on Positive Rexista Oxycodone Data
Zacks Equity Research - Zacks Investment Research - Fri Jan 15, 3:45PM CST
Shares of Intellipharmaceutics International Inc. (IPCI) surged significantly after it announced that the bioequivalence trials on Rexista Oxycodone XR extended release tablets have demonstrated bioequivalence to Purdue Pharma's Oxycontin.
IPCI: 1.73 (-0.03), AERI: 19.21 (-0.15), CORT: 5.35 (+0.02), PCRX: 40.37 (+0.74)
Intellipharmaceutics Announces Successful Bioequivalence Results for Abuse Deterrent Rexista(TM) Oxycodone XR
GlobeNewswire - Thu Jan 14, 6:30AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company", a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that pivotal bioequivalence trials of the Company's Rexista(TM) Oxycodone XR (abuse deterrent oxycodone hydrochloride) extended release tablets, dosed under fasted and fed conditions, had demonstrated bioequivalence to Oxycontin(R) (oxycodone hydrochloride) extended release tablets as manufactured and sold in the United States by Purdue Pharma LP. The study design was based on United States Food and Drug Administration ("FDA" recommendations and compared the lowest and highest strengths of exhibit batches of the Company's Rexista(TM) Oxycodone XR to the same strengths of Oxycontin(R). The results show that the ratios of the pharmacokinetic metrics, Cmax, AUC0-t and AUC0-f for Rexista(TM) vs. Oxycontin(R), are within the interval of 80% - 125% required by the FDA with a confidence level exceeding 90%.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
IntelliPharmaCeutics (IPCI) Rises: Stock Up 6.5% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 7:45AM CST
IntelliPharmaCeutics International Inc. (IPCI) was a big mover last session, as the company saw its shares rise over 6% on the day.
EARS: 1.71 (-0.14), IPCI: 1.73 (-0.03)
Intellipharmaceutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
GlobeNewswire - Thu Aug 25, 3:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"
, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the 18 Annual Rodman & Renshaw Global Investment Conference on September 13, 2016. Domenic Della Penna, Chief Financial Officer, will be presenting at 2:10 P.M. (Eastern Time) in the Lotte New York Palace Hotel in New York City. I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics Closes Public Offering for US$5.2 Million
GlobeNewswire - Mon Jun 06, 4:30PM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today the closing of its previously announced underwritten public offering of 3,229,814 units of common shares and warrants, at a price of US$1.61 per unit, for gross proceeds of approximately US$5.2 million. The Company sold units comprised of an aggregate of 3,229,814 common shares and warrants to purchase an additional 1,614,907 common shares. The underwriter also purchased additional warrants to acquire 240,390 common shares pursuant to the over-allotment option exercised in part by the underwriter. The warrants are exercisable immediately, have a term of five years and an exercise price of US$1.93 per common share. After underwriting discounts and commissions and estimated offering expenses, the Company received net proceeds of approximately US$4.6 Million.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
IIROC Trade Resumption - I
CNW Group - Fri May 27, 8:45AM CDT
Trading resumes in:
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
IIROC Trade Resumption - Intellipharmaceutics International Inc.
Newsfile Corp - Fri May 27, 8:42AM CDT
Trading resumes in:
IPCI: 1.73 (-0.03)
IIROC Trade Halt - Intellipharmaceutics International Inc.
Newsfile Corp - Fri May 27, 8:31AM CDT
The following issues have been halted by IIROC:
IPCI: 1.73 (-0.03)
Intellipharmaceutics Announces Pricing of $5.2 Million Public Offering of Common Shares and Warrants
GlobeNewswire - Fri May 27, 8:30AM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the pricing of an underwritten public offering of 3,229,814 units of common shares and warrants, at a price of US$1.61 per unit, equal to the closing price of the Company's shares on the NASDAQ on May 26, 2016. In connection with the offering, the Company will be issuing an aggregate of 3,229,814 common shares and warrants to purchase an additional 1,614,907 common shares. The warrants will be exercisable immediately, have a term of five years and an exercise price of US$1.93 per common share. After underwriting discounts and commissions and estimated offering expenses, the Company expects to receive net proceeds of approximately US$4.6 million.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
IIROC Trading Halt - I
CNW Group - Fri May 27, 8:30AM CDT
The following issues have been halted by IIROC:
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants
GlobeNewswire - Thu May 26, 4:24PM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it intends to offer units of its common shares and warrants in an underwritten public offering. Dawson James Securities, Inc. is acting as sole bookrunner for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceuticals International's CFO Domenic Della Penna Interviewed by The Life Sciences Report
Marketwired - Thu May 12, 8:02AM CDT
SAN FRANCISCO, CA--(Marketwired - May 12, 2016) - Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International Inc. (NASDAQ: IPCI) (TSX: I) has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report, as well as a robust pipeline of generic options for a variety of indications.
I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics Reports Director Election Results
GlobeNewswire - Tue Apr 19, 4:30PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"
, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reports, as required by TSX rules, that the six nominees, each of whom was an incumbent director of the Company, identified in the Management Information Circular dated March 11, 2016 (the "Circular" were elected as directors of the Company at the annual and special meeting of shareholders of the Company held today (the "Meeting". The voting results, as set out in the scrutineer's report for the Meeting, were as follows: I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics Announces First Quarter 2016 Results
GlobeNewswire - Fri Apr 15, 5:30AM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"
, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 29, 2016. All dollar amounts referenced herein are in United States dollars unless otherwise noted. I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference
GlobeNewswire - Tue Jan 19, 9:00AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"
, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the Noble Financial Capital Markets' 12 Annual Investor Conference on January 20, 2016. The presentation will take place at 9:00 A.M. (EST) at the Club Med, Sandpiper Bay, Florida. I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
Intellipharmaceutics Up on Positive Rexista Oxycodone Data
Zacks Equity Research - Zacks Investment Research - Fri Jan 15, 3:45PM CST
Shares of Intellipharmaceutics International Inc. (IPCI) surged significantly after it announced that the bioequivalence trials on Rexista Oxycodone XR extended release tablets have demonstrated bioequivalence to Purdue Pharma's Oxycontin.
IPCI: 1.73 (-0.03), AERI: 19.21 (-0.15), CORT: 5.35 (+0.02), PCRX: 40.37 (+0.74)
Intellipharmaceutics Announces Successful Bioequivalence Results for Abuse Deterrent Rexista(TM) Oxycodone XR
GlobeNewswire - Thu Jan 14, 6:30AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"
, a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that pivotal bioequivalence trials of the Company's Rexista(TM) Oxycodone XR (abuse deterrent oxycodone hydrochloride) extended release tablets, dosed under fasted and fed conditions, had demonstrated bioequivalence to Oxycontin(R) (oxycodone hydrochloride) extended release tablets as manufactured and sold in the United States by Purdue Pharma LP. The study design was based on United States Food and Drug Administration ("FDA" recommendations and compared the lowest and highest strengths of exhibit batches of the Company's Rexista(TM) Oxycodone XR to the same strengths of Oxycontin(R). The results show that the ratios of the pharmacokinetic metrics, Cmax, AUC0-t and AUC0-f for Rexista(TM) vs. Oxycontin(R), are within the interval of 80% - 125% required by the FDA with a confidence level exceeding 90%. I.TO: 2.26 (-0.04), IPCI: 1.73 (-0.03)
IntelliPharmaCeutics (IPCI) Rises: Stock Up 6.5% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 7:45AM CST
IntelliPharmaCeutics International Inc. (IPCI) was a big mover last session, as the company saw its shares rise over 6% on the day.
EARS: 1.71 (-0.14), IPCI: 1.73 (-0.03)
(0)
(0)